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Abstract: Lack of axon growth ability in the central nervous system poses a 
major barrier to achieving functional connectivity after injury. Thus, a non-
transgenic regenerative approach to reinnervating targets has important 
implications in clinical and research settings. Previous studies using knockout 
(KO) mice have demonstrated long distance axon regeneration. Using an 
optic nerve injury model, here we evaluate the efficacy of viral, RNAi and 
pharmacological approaches that target the PTEN and STAT3 pathways to 
improve long distance axon regeneration in wild type (WT) mice. Our data 
show that adeno-associated virus (AAV) expressing short hairpin RNA 
(shRNA) against PTEN (shPTEN) enhances retinal ganglion cell axon 
regeneration after crush injury. However, compared to the previous data in 
PTEN KO mice, AAV-shRNA results in a lesser degree of regeneration, likely 
due to incomplete gene silencing inherent to RNAi. In comparison, an 
extensive enhancement in regeneration is seen when AAV-shPTEN is coupled 
to AAV encoding ciliary neurotrophic factor (CNTF) and to a cyclic adenosine 
monophosphate (cAMP) analogue, allowing axons to travel long distances and 
reach their target. We apply whole tissue imaging that facilitates three-
dimensional visualization of single regenerating axons and document 
heterogeneous terminal patterns in the targets. This shows that some axonal 
populations generate extensive arbors and make synapses with the target 
neurons. Collectively, we show a combinatorial viral RNAi and 
pharmacological strategy that improves long distance regeneration in WT 
animals and provide single fiber projection data that indicates a degree of 
preservation of target recognition. 
Keywords: Axon regeneration, Retinal ganglion cell, PTEN, Axon injury, Axon 
guidance 
Introduction 
Following injury, axons in the adult central nervous system 
(CNS) generally fail to regenerate long distances and reinnervate their 
target. Using optic nerve injury and conditional knockout (KO) mice, 
we and others have previously demonstrated that deleting 
phosphatase and tensin homologue (PTEN) and suppressor of cytokine 
signaling 3 (SOCS3) in adult retinal ganglion cells (RGC) allows long 
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distance optic nerve regeneration and target reinnervation to some 
degree 1–3. Moreover, it was reported that PTEN KO combined with 
zymosan and cAMP analogue induces long distance regeneration and 
partial recovery of visual functions 4, providing a framework for 
developing reparative therapy. However, whether non-transgenic 
approaches that modulate PTEN alone or with other growth regulating 
factors can promote a similar level of RGC axon regeneration in wild 
type animals has not been directly addressed. Adeno-associated virus 
(AAV) lacks significant pathogenicity and has been used safely in 
clinical trials for a number of ocular and non-ocular diseases 5. 
Therefore, the first aim of this present study was to evaluate whether 
AAV vectors that incorporate RNA interference (RNAi) can suppress 
endogenous PTEN in adult RGCs and promote RGC axon regeneration 
in the adult mouse. Next, we examined whether combined viral RNAi 
and pharmacotherapy approaches that modulate PTEN and other 
growth promoters will further improve long distance regeneration of 
axons to their brain targets. 
On arriving at the final targets, the growth cones of long 
projecting axons switch from an extension program to one that 
facilitates target recognition and reconnection. One key feature during 
this process is the formation of axon arbors that facilitates connection 
with their proper target neurons. To visualize single axon and their 
entire arbors and to unequivocally assess axon terminals, several 
studies in model organisms including zebrafish have used single cell 
labeling and whole tissue imaging 6, 7. However, such techniques have 
not yet been established for the study of axon targeting in mammals. 
In our previous studies, we have described the use of optical clearance 
and whole tissue imaging to assess RGC axon regeneration in vivo. In 
this present study, we expand the application of these imaging 
techniques, establish single axon visualization and determine terminal 
morphology of regenerating axons within a visual target in mice. 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Gene Therapy, Vol 22, No. 10 (October 2015): pg. 811-821. DOI. This article is © Nature Publishing Group and permission 
has been granted for this version to appear in e-Publications@Marquette. Nature Publishing Group does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from 
Nature Publishing Group. 
4 
 
Results 
Evaluation of AAV2-shRNA mediated PTEN knockdown 
and RGC axon regeneration 
Here we sought to examine the degree of RGC axon 
regeneration after AAV-shRNA mediated PTEN knockdown. To this end, 
we first tested a shRNA strategy, based on SIBR vector system 8. In a 
SIBR vector, shRNA is located in an intron and flanked by sequences 
derived from mir155, an endogenous intronic shRNA. This design 
allows a single primary transcript to produce shRNA from intronic 
sequences, as well as an intact exon that encodes an enhanced green 
fluorescent protein (EGFP) reporter (Figure 1a). Furthermore, this 
design allows insertion of four separate shRNA sequences, 
concatenated in a single plasmid, each targeting a different region of 
PTEN (referred hereafter as “shPTEN4”), thereby increasing the 
probability of effectively silencing the gene of interest. Alternatively, 
we used a previously tested PTEN targeting sequence 9, 10 shown to be 
highly specific to PTEN (referred hereafter as shPTEN1)10. Since AAV 
serotype 2 has been shown to effectively transduce postmitotic 
neurons including the RGCs 11, these plasmids were then used to 
produce adeno-associated virus serotype 2 (AAV-shPTEN4 or 
shPTEN1). To evaluate the knockdown efficiency of PTEN, we initially 
incubated rat cortical neurons with either AAV-anti-luciferase-EGFP 
(AAV-EGFP) or AAV-shPTEN4. Seven days after treatment AAV-
shPTEN4 markedly suppresses the endogenous expression of PTEN as 
shown by immunocytochemistry (Figure 1b; n=2 biological replicates). 
To evaluate the gene knockdown efficiency in mouse RGCs, we 
injected AAV-shPTEN4 into the vitreous body of young adult C57BL/6 
mouse eyes. In cross-section immunohistochemistry performed two 
weeks after injection, transduced RGCs show a significant reduction of 
PTEN expression compared to control RGCs transduced with AAV-EGFP 
(Figure 1c). Flat-mounted retinae show over 90% transduction of 
RGCs by the AAV vector (Figure 1d; n=4). Quantification using 
western blot in cortical neurons (Figure 1e, f), and PTEN intensity 
analysis in retina sections (Figure 1g), we observe about 70% 
reduction in PTEN level after AAV-shPTEN4. Consistent with the 
previous study 9, 10, AAV-shPTEN containing a single targeting 
sequence (AAV-shPTEN1) led to approximately 70% reduction in PTEN 
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expression in adult RGCs (data not shown). As an initial test to 
examine the effect of PTEN knockdown on RGC axon regeneration, we 
injected AAV-shPTEN4, AAV-shPTEN1 or AAV-EGFP two weeks before 
an optic nerve crush. Anterograde labeling of regenerating axons by 
CTB injection occurred two days prior to sacrifice. As expected, we 
observed significant increases in the number of axons growing beyond 
the lesion site in mice receiving either AAV-shPTEN4 (6-fold increase) 
or AAV-shPTEN1 (4-fold increase) compared to AAV-EGFP treatment at 
0.2 mm from the lesion 4 weeks after injury (Figure 2a, b; 
n=5/group). We noticed however that the degree of regeneration in 
the AAV-shPTEN animals is less extensive than that of the PTEN KO 
mice (i.e. PTENf/f mice subjected to AAV-Cre injection) 1. At 4 mm 
distal to the lesion (i.e. near the chiasm), we did not observe 
regenerating axons in the AAV-shPTEN animals. On the other hand, 
more than 20 axons per one optic nerve section were seen at this 
distance in the PTEN KO animals treated with AAV-Cre 1. Since we 
have previously shown that the level of axotomy-induced cell death is 
reduced by PTEN deletion in RGCs 1, we also assessed whether AAV-
mediated PTEN knockdown will similarly enhance RGC survival. By 
using an antibody against βIII tubulin (TUJ1) to immunostain viable 
RGCs, we observed that AAV-shPTEN4 treatment results in a 2-fold 
increase in RGC survival rates compared to control mice (Figure 2c, d). 
Unlike the difference seen in regeneration rate, this increase in 
survival is similar to that seen in the PTEN KO mice 1. Overall, these 
data demonstrate that PTEN knockdown, albeit at a lower level than 
the PTEN KO mice, increases RGC axon regeneration in adult mice. 
 
Figure 1: AAV-shRNA mediated suppression of PTEN 
(a) A map of AAV2-shPTEN4 construct. Control and shPTEN constructs contain EGFP 
reporter. (b) Immunocytochemistry showing expression of GFP, PTEN, and beta III 
tubulin (TUJ1) in cultured cortical neurons incubated with either AAV-anti-luciferase-
EGFP (control) or AAV-RNA against PTEN (AAV-shPTEN4) for 7 days. These are 
representative micrographs from 2 separate experiments. (c) Retina sections following 
control AAV2-EGFP (EGFP) or AAV2-shPTEN4 injection show PTEN knockdown in 
ganglion cell layer. (d) Flat-mounted retina 2 weeks following intravitreal injection of 
AAV2-shPTEN4, stained with antibodies against GFP and TUJ1 shows >90% 
transduction efficiency in RGCs. (e) Western blot of protein lysates extracted from 
cultured cortical neurons showing PTEN level at 7 days after the addition of AAV-
shPTEN4 or AAV-EGFP. (f) Quantification of PTEN level from the western blot. Values 
are represented as ratio of PTEN to βIII-tubulin (n=3 biological replicates). (g) 
Quantification of PTEN expression in RGCs in retinal sections, measured by ImageJ 
densitometry method. Intensity unit is an arbitary value. Error bars, SEM. Scale bars, 
20 μm. 
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Figure 2: Assessment of RGC axon regeneration following AAV-shRNA 
mediated knockdown of PTEN 
(a) Representative optic nerve sections of mice receiving AAV2-shPTEN4 or control 
AAV2–EGFP injection. Red asterisk, lesion site. (b) Quantification of regenerating 
axons in control and shPTEN treated animals (n=5/group) at different distances from 
the lesion site. The data are represented as mean number of axons per section. (c) 
Representative images of TUJ1 stained wholemount retinae for both groups. (d) 
Quantification of RGC density (n=5/group). Error bars, SEM; ****: p<0.0001; ***: 
p<0.001, *p<0.05 ANOVA with Bonferroni correction (b) and student’s unpaired t-test 
(d). Scale bars, 100 μm (a); 20 μm (b). 
Assessment of combinatorial AAV and RNAi strategy to 
enhance long distance axon regeneration 
PTEN is one of many factors known to regulate RGC axon 
regeneration. Other strategies that were shown to facilitate long 
distance RGC axon regeneration include deletion of SOCS3 or Klf4, and 
elevation of CNTF 2, 12–18. Given the synergistic effects induced by 
combining PTEN KO mice with modulation of the CNTF/STAT3 
pathway, we sought to test combining RNAi and AAV approach to 
target these factors and further improve regeneration. First, we 
generated AAV expressing shRNA against SOCS3 using the SIBR 
vector system, but this failed to drastically knockdown SOCS3 
expression (data not shown). Given that elevation of CNTF using AAV 
vector allows significant increase in long distance regeneration in the 
injured optic nerve 12–15, 19, we then tested combining AAV-CNTF with 
AAV-shPTEN. To mimic clinical situations, all animals in subsequent 
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experiments received intravitreal injection immediately after an optic 
nerve crush. Consistent with the previous studies, we observed that 
animals receiving the AAV expressing a secretable form of CNTF alone 
show significant increase in regeneration (Figure 3a, b). Double 
combination of AAV-shPTEN with AAV-CNTF did not result in a 
significant increase compared to AAV-CNTF alone (Figure 3a, b). Next 
we tested the effect of biweekly application of cell permeant cAMP 
analogue, cpt-cAMP in improving axon regeneration in the background 
of AAV-shPTEN and AAV-CNTF. Previous studies have shown that cpt-
cAMP can facilitate CNS axon regeneration by recruiting multiple 
mechanisms including down-regulation of SOCS3 as well as activating 
mitogen activated protein kinase (MAPK) and protein kinase A (PKA) 
pathways 17, 20. Indeed, this three-way combination of AAV-shPTEN4, 
AAV-CNTF and cpt-cAMP (hereafter referred as “PCC” treatment) led to 
a marked increase in the number of regenerating axons; there is more 
than 3-fold increase in the number of axons regenerating up to 2 mm 
distal to the lesion compared to AAV-CNTF alone (Figure 3a, b; n=6–
8/group). Of note, double combination of shPTEN and cpt-cAMP does 
not result in an obvious increase in axon regeneration compared to 
shPTEN treatment alone (Figure 3b). We also assessed RGC survival 
rates in the combinatorial paradigm using TUJ1 immunostaining, and 
observed that mice receiving PCC treatment have similar RGC survival 
(i.e. over 20% survival compared to the contralateral uninjured retina) 
compared to AAV-shPTEN4 and AAV-CNTF/cpt-cAMP-treated groups in 
this post-injury treatment paradigm (Figure 3c, d). Overall, these 
results show that concomitant modulation of PTEN, CNTF and cAMP 
using a combination of viral, RNAi and pharmacotherapy approaches 
greatly enhances long distance axon regeneration. 
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Figure 3: AAV-shPTEN, AAV-CNTF and cpt-cAMP further improves lengthy RGC 
axon regeneration 
(a) Representative optic nerve sections of mice receiving various AAV treatments. 
Control, AAV2-EGFP; shPTEN4, AAV2-shPTEN4; CNTF, AAV-CNTF; CNTF/cAMP, AAV2-
CNTF/cpt-cAMP; PCC, AAV2-shPTEN4/AAV2-CNTF/cpt-cAMP. Red asterisk, lesion site. 
(a′) Higher-magnification images of the boxed area in A. (b) Quantification of 
regenerating axons at different distances from the lesion site (n=6–8/group). *: 
p<0.05, Bonferroni test (PCC significantly different to AAV-CNTF and AAV-CNTF/cpt-
cAMP groups). (c) Representative images of TUJ1 stained wholemount retinae from 
mice receiving various AAV treatments. (d) Quantification of RGC density 
(n=6/group). Error bars, SEM. Scale bars, 100 μm (a); 20 μm (d). 
Assessment of RGC axon regeneration in PCC-treated 
mouse brains 
Next we examined the extent to which the regenerate RGC 
axons in PCC-treated animals extend beyond the optic chiasm and 
reach their visual targets. To this end, we used tissue clearing and 
LSFM to image regenerating axons in whole mouse optic nerves and 
brains without the data loss that results from tissue sectioning 21, 22. 
This protocol uses THF and BABB to turn optic nerves and brains 
relatively transparent (Figure. 4a), allowing visualization of the entire 
optic projection in whole tissues (Figure 4b). Animals received crush 
injury followed immediately by PCC treatment or AAV-EGFP injection. 
By 4 to 6 weeks post-injury, regenerating axons reach the optic 
chiasm. About 20% of these axons extend into the opposite, uninjured 
optic nerve (Figure. 4c–e). Similar or higher numbers of regenerating 
axons are found in the ipsilateral compared to the contralateral optic 
tract (Figure 4c–e) en route to more distal visual targets. Similar to 
the previous studies 14, 22, 23, at 10–14 weeks post-injury (n=13), path-
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finding errors are evident in the brain as most axons extend dorsally, 
parallel to the third ventricle and do not find the distant brain targets 
(i.e. superior colliculus (SC) and lateral geniculate nucleus(LGN)) (data 
not shown). 
 
Figure 4: Tissue clearing and ultramicroscopic assessment of axonal 
trajectories in the optic chiasm of PCC animals 
(a) Adult mouse brains with and without tissue clearing. The eyes and optic nerves are 
attached to the brain. (b) Top view of an intact mouse brain. Brain from an uninjured 
mouse shows the entire trajectory of CTB-labeled RGC axons: all visual targets are 
visible, including the suprachiasmatic nucleus, lateral geniculate nucleus, and superior 
colliculus, ipsi- and contralaterally to the injected eye. (c) A horizontal optical slice 
from an unsectioned brain of a PCC-treated animal shows CTB-labeled axons in the 
optic chiasm. (c′) Higher-magnification of the boxed area in c. (d) Reconstruction of 
traced axons through the chiasm. (e) Quantification of axonal trajectories into 
different regions in 5 different cases (i.e. ipsi- and contralateral optic tracts, 
contralateral optic nerve, and hypothalamic regions). Contra, contralateral; Hypothal. 
Hypothalamic region; Ipsi, ipsilateral; IOT, ipsilateral optic tract; LGN, lateral 
geniculate nucleus; ON, optic nerve; OT, optic tract; OX, optic chiasm; 3rd V, 3rd 
ventricle; SC, superior coliculus; SCN, suprachiasmatic nucleus. Scale bars, 100 μm. 
Characterizing individual axons’ morphologies in a 
visual target 
Importantly, regenerating axons are found in and around RGCs’ 
first brain target the suprachiasmatic nucleus (SCN), located directly 
above the optic chiasm (Figure 5a). In control animals treated with 
AAV-EGFP (n=14), we do not detect any CTB-labeled axons in the 
brain (Figure 5b). The growing tips of elongating axons sense their 
post-synaptic partners within the target to begin to form arbors and to 
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establish synaptic connection. Do the adult RGC axons regenerating 
long distances through the optic nerve have the ability to sense their 
target and arborize? Traditionally, morphological analysis of axon 
terminals and arborization is carried out in histological sections. 
However, tissue sections provide limited spatial information, making it 
difficult to determine unequivocally whether the axon terminals are in 
fact located within a correct region. It is also difficult to ascertain the 
extent of arborization, a key step toward establishing a proper target 
reconnection. Here, we sought to expand the application of whole 
tissue imaging techniques and to evaluate qualitatively the growth 
behavior as axons reach a correct visual target, the SCN. To this end, 
we scanned individual 2D LSFM images of mouse brains to visualize 
CTB-labeled axons. We took advantage of the fact that the number of 
axons that reach the SCN is small (ranging between 5 and 40 axons 
per animal), allowing us to visualize, trace, and sample single axons 
and their entire arbors. The vast majority of PCC treated animals (11 
out of 13 mice) had regenerating axons in the SCN. Figure 5 shows 
examples of two different animals with regenerating RGC axons 
reaching the SCN (Figure 5c, d). We were able to trace all visibly 
distinct axons in 2D optical slices and then compile these slices into a 
3D reconstruction (Figure 5e–j). In total, we traced 18 axons that 
reach the SCN. Overall, we observe at least four different re-growth 
patterns in and around the SCN. First, some axons approach the SCN 
but turn and bypass the region. Figure 5e shows an example of such 
behavior where an axon bifurcates outside the SCN and its branches 
extend and wrap around the SCN, suggesting that these axons may be 
repelled and actively prevented from entering this nucleus. Second, 
some axons enter the SCN, but they traverse and their terminals are 
found outside the region (Figure 5f). In this category, axons often 
branch within the SCN but the arbors exit and continue to extend 
outside the SCN (Figure 5g). Thus, these axons appear to lack signals 
that facilitate target recognition. Third, terminals of some axons are 
found inside the SCN (Figure 5h). Fourth, there are axons that 
generate complex arbors within the target (Figure 5i, j). Figure 5i 
shows tracing of such fiber entering the SCN and generating complex 
arbors. Immediately after entering the contralateral SCN, this axon 
bifurcates and its branches subsequently generate multiple arbors. The 
branches stemming from this individual axon extend and cover a large 
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field area within the SCN, suggesting the possibility that they may 
have made synapses with multiple SCN neurons. 
 
Figure 5: Ultramicroscopic visualization of axonal projections in mouse visual 
target 
(a) Optic chiasm, optic tract and SCN shown by CTB labeling in a cleared, uninjured 
brain. (b) Bottom view of a brain containing the SCN (i.e. dotted circles) imaged from 
a brain of an injured control mouse subjected to AAV-EGFP injection. None of the 
control animals had regenerating axons in the brain. (c) and (d) Bottom view of brains 
of two different PCC-treated animals showing regenerated axons in the chiasm and 
SCN. Yellow arrowhead indicates a regenerating axon extending into the SCN. Yellow 
arrow indicates distal end of the same axon showing continued growth beyond the 
SCN. White arrows in d indicate extensive arborization. (e–j), reconstructions of single 
axons showing various growth patterns. In (e), an axon bypasses the target. In (f) 
and (g), axons traverse the target. In (h), axon terminals are found within the SCN. 
In (i) and (j), axons enter the SCN and form complex arborization. ON, optic nerve; 
Uninj, uninjured; SCN, suprachiasmatic nucleus. Scale bars, 100 μm. 
Synaptogenesis 
To find evidence of re-synaptogenesis by regenerated axons, we 
performed immunohistochemistry using an antibody against vesicular 
glutamate transporter 2 (Vglut2), a major presynaptic protein of RGCs. 
We observe that some CTB-labeled axons in the SCN (the anatomical 
location depicted in Figure 6a) have Vglut2-positive patches at bouton-
like structures and along the axonal length (Figure 6b), suggesting an 
accumulation of the molecular machinery characteristic of a 
presynaptic terminal. To further confirm the ability of regenerating 
axons to make reconnection with the target neurons, we used the 
trans-synaptic reporter mouse line, iZ/WAP 24. These transgenic mice 
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express a Cre recombinase-inducible WGA under the direction of the 
CMV, cytomegalovirus, promoter and serves as a reporter strain, with 
successful Cre excision being indicated by WGA expression in Cre-
expressing neurons. WGA acts as a trans-synaptic tracer, allowing 
identification of the synaptic contacts of Cre-expressing neurons 24. In 
normal animals, between 40–80% of RGCs expressed WGA at 2 weeks 
following intravitreal AAV2-Cre injection as shown by 
immunohistochemistry (Figure 6c). In accordance, many WGA+ cells 
(i.e. cells that are post-synaptically connected with RGCs) are visible in 
the SCN of uninjured animals (Figure 6d). Similarly, WGA+ cells are 
present in the LGN in uninjured animals (Figure 6e). In contrast, no 
WGA+ cells are detected in injured animals receiving control AAV2-
EGFP injection (n=5; Figure 6f). In some PCC animals (3 out of 10 
animals), we observe WGA+ cells in the SCN in close proximity to CTB+ 
axons, indicating that these regenerate RGCs reform synapses with the 
target (Figure 6g, h). Overall, these data suggest that following the 
combinatorial treatment, individual regenerating axons possess 
varying capacity to recognize the target, and are able to form 
synapses and reconnect with the target neurons. 
 
Figure 6: Regenerate axons following PCC treatment form synapses in the 
SCN 
(a) Schematic coronal brain section showing the SCN marked in a dotted red 
rectangle. (b) CTB-labeled axons (red) in the SCN express presynaptic marker Vglut2 
(green). (b′) High-magnifications of the boxed area in (b), with XZ and YZ projections 
at the yellow crosshairs. (c) Retinal cross section showing RGCs expressing WGA 
(green) six weeks following AAV-Cre injection in iZ/WAP mice. DAPI (blue) is used in 
these tissue sections for nuclear staining. (d) WGA+ cells in the SCN of an uninjured 
animal. WGA (green) and DAPI (blue). (e) WGA+ cells in the LGN (as marked by 
dotted line) of an uninjured animal. WGA (green) and DAPI (blue). (f) No WGA+ cells 
are detected in the injured AAV-EGFP control mice (n=5). (g) Low magnification 
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coronal brain section showing the SCN of an injured PCC animal, marked in a yellow 
circles immunostained with antibodies against WGA. CTB, red; DAPI, blue. (h) High 
magnification of the dotted area in (g) showing CTB+ axons (red) wrapping or making 
close contact with WGA+ cells in the SCN. Scale bars, 50 μm. 
Discussion 
Previous studies have demonstrated that RGCs induced to 
regenerate in PTEN KO mice travel the entire length of the optic nerve 
1 or, in combination with other factors, reach the targets 3, 25 and 
induce partial recovery of visual functions 4. While these KO mouse 
studies have revealed some key molecular mechanisms underlying 
axon regeneration, it remained to be seen whether a non-transgenic 
approach that targets PTEN alone or in combination can also promote 
a similar degree of optic nerve regeneration and target re-innervation. 
Since axonal damage in the optic nerve causes irreversible loss of 
visual functions in glaucoma and after trauma, therapeutically relevant 
strategies that promote regeneration through the optic nerve and 
reconnection have important clinical implications. More broadly, 
therapeutic strategies designed to improve RGC axon regeneration 
may provide ideas to treat injuries in other long CNS tracts including 
the spinal cord. 
Previous studies have reported successful uses of non-
transgenic PTEN blockers to promote axon regeneration after nerve 
injury. Following a spinal cord injury, PTEN antagonist peptide or AAV-
shPTEN were shown to improve axon regeneration in the spinal cord 9, 
26, 27. Others have demonstrated that PTEN inhibitor 
bisperoxovanadium enhances regeneration of sensory axons 28. 
However, it has not been established whether AAV-shRNA that 
suppresses PTEN would induce regeneration in RGC axons. More 
importantly, whether combining RNAi knockdown of PTEN with other 
non-transgenic strategies known to increase neuron’s growth ability 
could further enhance long distance axon regeneration has not been 
directly addressed. 
Here we compare rates of RGC axon regeneration following 
PTEN knockdown using two AAV vectors each carrying different PTEN 
target sequences. Despite protein knockdown efficacy as high as 70–
90%, the effect on axon regeneration is far less robust than that seen 
after PTEN deletion in transgenic mice. This difference could be 
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attributed to potential off-target effects associated with RNAi (i.e. 
silencing of pro-regenerative genes); however, this is unlikely since 
the two AAV-shPTEN vectors target different sequences within PTEN. 
Furthermore, the shPTEN1 used in this study was previously shown to 
cause no detectable off-target effects when the closest potential off-
target genes were examined 10. Thus it is more likely that the weaker 
regeneration seen with RNAi is due to incomplete PTEN silencing, a 
common limitation in the use of shRNA technology 29. In many 
instances, a low level of residual expression may still be sufficient for 
gene function. For example, conditional PTEN heterozygote mice 
typically display less severe phenotypes than null-homozygotes 30. In 
accordance, we observe no obvious increase in axon regeneration after 
heterozygous PTEN ablation (i.e. PTENf/+ mice subjected to intravitreal 
AAV-Cre injection) (data not shown). 
Virally expressed CNTF represents a potent way to induce long 
distance RGC axon regeneration. Consistent with the previous studies 
12–15, 19, AAV-CNTF alone results in a significant induction of long 
distance regeneration, and cAMP analogue did not significantly 
enhance axon regeneration in the background of AAV-CNTF 20, 31. 
However, combined treatment of cAMP analogue, AAV-shPTEN, and 
AAV-CNTF greatly enhanced regeneration and allowed more axons to 
reach the brain. Interestingly, similar enhancement in regeneration 
has been reported when PTEN depletion and cAMP analogue are 
combined with zymosan 25. Mechanistically, previous studies have 
demonstrated that axon regeneration induced by PTEN depletion relies 
on downstream activation of Akt/mammalian target of rapamycin 
(mTOR). On the other hand, axon regeneration induced by SOCS3 
deletion or CNTF elevation is dependent on activation of the signal 
transducer and activator of transcription-3 (STAT3) pathway 1–3. 
Multiple signaling pathways and molecules have been suggested to 
mediate the pro-regenerative effect of cAMP, including activation of 
MAPK, PKA and cAMP response element-binding protein (CREB) 17, 20, 
32. It has also been shown that cAMP can reduce CNTF-induced SOCS3 
expression, diminishing the effect of this negative feedback system 33. 
Thus, it is likely that PCC treatment activates multiple pathways and 
mounts complementary growth programs that ultimately lead to more 
robust regeneration. However, the intricate mechanisms underlying 
the crosstalk between these molecules are unknown and await future 
elucidation. 
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While mammalian RGCs can be induced to regenerate along the 
optic nerve, axons fail to correctly pathfind to their distant targets, the 
LGN and SC. These observations are consistent with the notion that 
axons do not simply re-use degenerating optic tracts 34. Nonetheless, 
some regenerating axons successfully reach a target that is located 
much closer to the eye, the SCN. Using whole tissue imaging, we 
provide single fiber projection data that unequivocally reveal the 
behaviors of regenerating RGC axons as they reach this target. During 
development, growing RGC axons navigate towards their targets 
where they arborize and form synapses 7, 35, 36. The transition from 
axon extension to target recognition and axon branch initiation is 
regulated by spatiotemporal expression of receptors and respective 
ligands in the axons and target regions. In particular, local expression 
of growth factors such as brain derived neurotrophic factor (BDNF) and 
fibroblast growth factor 2 (FGF2) have been shown to play critical roles 
in modulating axon arborization and synaptic formation in the visual 
targets 6, 36, 37. Do adult mammalian brains express relevant target 
cues, and do the regenerate RGC axons retain the capacity to 
recognize correct targets? These questions have been addressed 
extensively using peripheral nerve graft experiments, in which 
transected RGC axons are permitted to regenerate through a segment 
of peripheral nerve and reinnervate their targets 38–44. These studies 
have indicated the presence of considerable axon arborization and 
synaptic connection in the SC and concluded that both optic axons and 
target neurons in adult mammals retain recognition ability. 
In this study, use of single fiber tracing decisively shows 
extensive axon arborization, thereby providing morphological evidence 
of some axons’ ability to recognize and reconnect with a visual target, 
while other axons seem to be repelled from entering this site. Of note, 
we observed the presence of synaptic marker (i.e. Vglut2) in a variety 
of cases that include animals with relatively high number of axons in 
the SCN as well as animals with relatively low axon numbers. Thus, it 
is likely that regenerated axons with or without extensive arborization 
may make synapses in the SCN. This is further supported in trans-
synaptic reporter mouse line in which WGA labeled cells were observed 
in SCN, indicating that the axons indeed made connection with the 
target. Recently, it was reported that axons of pten/socs3 KO animals 
make synaptic connections with SCN neurons following pre-chiasmic 
lesion 45. However, it is not established whether the PCC in this study 
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or the pten/socs3 KO allows restoration of visual functions. Our lab is 
currently investigating this question. Since the SCN is normally 
innervated by a small population intrinsically photosensitive RGCs 
(ipRGCs), a question rises as to whether there is any degree of 
neuron-target selectivity in adult animals. While several studies have 
used single cell labeling to characterize axon targeting and branching 
patterns of different RGC types in lower species such as zebrafish and 
Drosophila 7, 37, no such comprehensive data currently exist for 
mammals. In this regard, it will be very interesting in the future to 
define normal targeting and arborization patterns of individual RGC 
types and assess the degree to which regenerating axons recapitulate 
this process. In light of different transgenic mouse lines in which 
distinct RGC subtypes including ipRGCs are labeled, initiation of such 
analysis may be feasible 35, 46. 
In summary, our data highlight the limitation of shRNA 
technology in fully mimicking KO regeneration phenotypes, and 
indicate that combining AAV, shRNA, and pharmacotherapy represents 
an alternative and effective strategy to improve axon regeneration and 
importantly, target reconnection in WT animals. Further, extended 
application of whole brain imaging underscores technical improvement 
in conducting a systematic evaluation of axon targeting and uncovers 
heterogeneous and distinct terminal patterns by the individual 
regenerating axons. 
Materials And Methods 
Cloning and generation of AAV2-shPTEN, AAV2-Cre and 
AAV2-CNTF 
To suppress PTEN expression, we adopted a shRNA strategy, 
based on SIBR vectors 8 in which shRNA is located in an intron and 
flanked by sequences derived from mir155, an endogenous intronic 
shRNA. To maximize the probability of effectively targeting PTEN, four 
separate shRNA sequences, each targeting a different region of PTEN 
were concatenated in a single plasmid, which was then used to 
produce adeno-associated virus (AAV-shPTEN). Four sequences that 
target both mouse and rat PTEN were designed using siDIRECT 
website and design rules 47: four targeted sequences for PTEN are: 
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GCAGAAACAAAAGGAGATATCA;GATGATGTTTGAAACTATTCCA;GTAGAG
TTCTTCCACAAACAGA;GATGAAGATCAGCATTCACAAA. Oligonucleotides 
encoding hairpin loops that included these sequences and deliberate 
mis-matches in the non-target strand were synthesized, annealed, 
inserted into the SIBR knockdown vector, and concatenated into a 
single plasmid as described 8. A region of the SIBR knockdown vector 
comprising the ubiquitin promoter, intronic sequences, knockdown 
cassette, and EGFP open reading frame was cloned into an AAV-
compatible plasmid (AAV-MCS, Stratagene), from which the CMV 
promoter, intron and MCS were removed. SIBR anti-luciferase control 
shRNA was transferred to AAV plasmid similarly. To construct AAV 
expressing a secretable form of CNTF, an AAV-compatible SIBR vector 
was created by PCR-amplifying the knockdown cassette of a SIBR 
vector with primers that created 5′ Mlu1 
(ACGCGTTTAAACTGGCCTCCGCGCC) and 3′ Cla1 
(ccgccgATCGATTCACTTGTACAGCTCGTCCA) sites. This cassette was 
inserted into a Stratagene AAV plasmid, replacing the CMV promoter 
and B-globin intron. The resulting AAV-SIBR plasmid was then 
modified via bridge PCR to create KpnI and BglII sites to flank the 
EGFP open reading frame. Plasmid DNA encoding human CNTF was 
purchased from OpenBiosystems (Accession: BC068030) and the open 
reading frame was amplified using a forward primer that incorporated 
both a 5′ Kpn1 restriction site and the NGF signal peptide sequence 
(GGTACCATGTCCATGTTGTTCTACACTCTGATCACAGCTTTTCTGATCGGCA
TACAGGCGGCTTTCACAGAGCATTCACCGC) and a reverse primer that 
incorporated 3′ BglII site (AGATCTCTACATTTTCTTGTTGTTAGCAA). 
PCR-amplified CNTF was then used to replace the EGFP ORF in the 
AAV-SIBR vector via standard restriction digest and ligation. All 
enzymes were purchased from New England Biolabs. Plasmids were 
then used to produce adeno-associated virus serotype-2 (AAV2) (1–
4×1013 particles/ml) at the University of Miami Viral Vector Core. For 
making AAV2 expressing Cre recombinase, the cDNA of Cre was 
inserted downstream of the CMV promoter/β-globin intron enhancer in 
the plasmid pAAV-MCS (Stratagene), containing the AAV2 inverted 
terminal repeats and a human growth hormone polyA signal. pAAV-RC 
(Stratagene) that encodes the AAV2 genes (rep and cap) and the 
helper plasmid (Stratagene) that encodes E2A, E4 and VA were used 
for co-transfection in 293T cells to generate recombinant AAV. 
Plasmids were then used to produce adeno-associated virus serotype-2 
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(AAV2) (1–4×1013 particles/ml) at the University of Miami Viral Vector 
Core. 
Animals 
All animal procedures were performed with the approval of 
IACUC at University of Miami. C57BL/6 (male or female; Charles River 
Laboratory) mice were used in this study, except for the wheat germ 
agglutinin (WGA) experiment in Figure 8 in which iZ/WAP mice 
(B6;129-Tg(CMV-Bgeo,-WGA,-ALPP)1Mgmj/J, Jackson Laboratory; 
Stock number, 017524)24 were used. The age of animals used at the 
start of each experiment was between 4–6 weeks. Animals were 
randomly assigned to different treatment groups. The investigator who 
analyzed the data was not blinded to the animal identity. The numbers 
of animals (n/group) used for each experiment range from 3 up to 14 
depending on the type of experiment and are listed in the figure 
legends. 
Intraorbital optic nerve crush 
The optic nerve was exposed intraorbitally and crushed with 
jeweler’s forceps (Dumont #5; Roboz) for 10 seconds approximately 1 
mm behind the optic disc. To preserve the retinal blood supply, care 
was taken not to damage the underlying ophthalmic artery. After the 
surgical procedure, mice received a subcutaneous injection of 
buprenorphine (0.05 mg/kg, Bedford Lab) as post-operative analgesic. 
Eye ointment containing atropine sulphate was applied preoperatively 
to protect the cornea during surgery. 
Intravitreal injection 
For each intravitreal injection, a glass micropipette was inserted 
into the temporal eye posterior to the ora serrata and deliberately 
angled to avoid lens damage. Approximately 2 μl of vitreal fluid were 
withdrawn before injection to accommodate the same volume of either 
virus mix or cholera toxin β-subunit (CTB) conjugated with Alexa 555 
(Invitrogen). AAV was administered either 2 weeks before or 
immediately after crush. cpt-cAMP (8-(4-chlorophenylthio) adenosine-
3′,5′-cyclic monophosphorothioate; Sigma Aldrich; 50 μM) was 
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injected intravitreally on the day of crush and biweekly (i.e. every 
other week) thereafter until euthanasia 25. CTB (2 μg/μl) was injected 
2–4 days prior to euthanasia. To visualize RGC projection in normal 
mice, CTB was injected and animals were euthanized 2–4 days later. 
After the completion of eye injection, animals received the same post-
operative treatment as described above. 
Immunohistochemistry/immunocytochemistry 
Animals were perfused transcardially with PBS followed by 4% 
paraformaldehyde (PFA) in PBS, then tissues dissected and post-fixed 
with 4% PFA in PBS for 1 hour at room temperature. For histological 
sectioning, samples were cryoprotected by incubating in 30% sucrose 
in PBS for 48 hours. Optic nerves and retinae were cryosectioned to 10 
and 20 μm thickness, respectively. Tissue sections were blocked in 5% 
normal goat serum and 0.3% Triton X-100 in PBS for 1 hour and 
incubated with primary antibodies diluted in blocking buffer overnight 
at 4°C, followed by 1 hour incubation with secondary antibodies at 
room temperature. For cortical neuron immunocytochemistry, cells 
were fixed for 15 minutes in 4% PFA, washed with PBS and stained as 
described above. Primary antibodies used were anti-βIII-tubulin 
(1:800; Covance; #PRB-435P), PTEN (1:200; CST; #9559S), vesicular 
glutamate transporter 2 (Vglut2) (1:500; Synaptic Systems; 
#135304), wheat germ agglutinin lectin (WGA) (1:100; Sigma Aldrich; 
#T4144-1VL) and GFP (1:1,000; Abcam; #ab13970). All secondary 
antibodies (used at dilution of 1:400; Cy2, Cy3 or Cy5) were 
purchased from Jackson ImmunoResearch. 
Measurement of PTEN immunoreactivity 
The mean PTEN staining intensity in RGCs was measured using 
ImageJ software. Values for PTEN were based on 8 cells per section, 2 
sections per case, and 3 per groups. Only GFP+ cells in the ganglion 
cell layer with visible axon projection (i.e. RGCs) were selected for 
measurement. As negative controls, we omitted the primary antibody. 
Individual mean values were corrected by staining levels in the 
corresponding negative controls (i.e. background subtracted) and then 
averaged across each group. 
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Cortical cell culture 
Mixed cortical cultures from P2 rat pups were prepared as 
previously described 48. Briefly, cells were dissociated by sequential 
digestion in papain (20 U/mL, Worthington) and trypsin (2.5%, 
Invitrogen), then cultured in supplemented Neurobasal media 
(Invitrogen) in 24-well Falcon plates on a substrate of PDL (100μg/mL, 
Sigma) and laminin (100μg/mL, Cultrex) at a density of 50,000 cells 
per well. AAV2-shPTEN or AAV2-anti-luciferase (4×108 total particles) 
were applied. Cultures were maintained at 37° C in a humidified CO2 
incubator for six additional days, with media exchanged every other 
day, then fixed in 4% paraformaldehyde (PFA, Sigma)/4% Sucrose 
(Sigma). 
Western blot 
Cortical cells were lysed with RIPA buffer. The protein 
concentration of the supernatant was determined using the Bio-Rad 
(Hercules, CA) protein assay reagent. Approximately 20 μg of protein 
was loaded and separated in a 10% acrylamide–Bis solution (Bio-Rad) 
gel. The protein was transferred onto Hybond-C Super membrane 
(Amersham Biosciences, Little Chalfont, UK) and blocked with 5% skim 
milk in 0.1% Tween 20 in PBS (TPBS). The membranes were incubated 
with anti-PTEN (1:1000; CST; #9559S) or anti-βIII tubulin (1:2000; 
Covance; #PRB-435P) in 5% BSA in TPBS overnight at 4°C. The 
membranes were incubated in biotinylated secondary antibody at a 
1:5,000 dilution for 1 hour at room temperature. The membranes were 
incubated with HRP-conjugated antibody (Babco) before the labeled 
proteins were detected using the ECL agent (Pierce, Rockford, IL), 
following the supplier’s manual. The intensity of each band was 
quantified using the Image J. The relative level of PTEN was expressed 
as the ratio to βIII-tubulin. The quantification was the average 
calculated from three biological replicates (i.e. three independent 
cortical cell preparations). 
Cell survival and axon regeneration quantification 
To quantify regenerating axons, the crush site was identified by 
tissue morphology and CTB signal intensity, and the number of CTB+ 
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axons that projected various distances from the lesion was recorded. 
At least 4 sections were counted for each animal. To quantify RGCs, 
the number of TUJ1+ cells in the ganglion cell layer of at least 4 non-
consecutive retina sections per animal was counted. 
Tissue clearing 
Optic nerves and brains were prepared as described above and 
post-fixed overnight. Detailed description of tissue clearing is provided 
in our recent manuscripts 22. Samples underwent dehydration by 
incubation in increasing concentrations of tetrahydrofuran (THF, 
Sigma-Aldrich) solutions. Optic nerves were incubated for 15 minutes 
each in 50% THF (diluted in water v/v), 80% THF, and 100% THF. 
Dehydrated optic nerves were rendered clear by incubating in BABB (a 
mixture of benzyl alcohol and benzyl benzoate (Sigma-Aldrich) at a 
ratio of 1:2) for 20 minutes. Adult mouse brains were gradually 
dehydrated with 50% THF for 12 hours, 80% THF for 12 hours, and 
100% THF for 3 × 12 hours, and cleared in BABB for 12 hours with 
constant shaking before imaging. 
Light Sheet Fluorescence Microscopy (LSFM) and axon 
tracing 
LSFM was performed as previously described 21, 49. For each 
optic nerve and brain between 100 and 500 optical slices were imaged 
with LSFM (LaVision) at a scan speed of 0.5–1.5 s per slice. Images 
were collected at 2 to 5μm increments in the Z axis. Images, and 3D 
volume rendering were prepared using Imaris software v7.6.1 
(Bitplane). CTB-labeled RGC axons in the brain were traced using 
Imaris Filament Tracer Module and SCN boundaries were marked with 
Imaris Surface Module. Axons were identified and manually traced in 
individual 2D optical slices (z stacks) and compiled to give a 3D 
reconstruction. 
Examination of trans-synaptic WGA labeling in iZ/WAP 
mice 
Transgenic mice (B6;129-Tg(CMV-Bgeo,-WGA,-ALPP)1Mgmj/J, 
Jackson Laboratory; Stock number, 017524)24 that express Cre 
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recombinase-inducible WGA under the direction of the CMV, 
cytomegalovirus, promoter received optic nerve crush followed 
immediately by AAV-EGFP or PCC injection. One weeks following 
injury, AAV-Cre was injected intravitreally to induce WGA expression in 
RGCs. Five weeks after AAV-Cre injection, animals were perfused and 
tissues were collected for WGA immunohistochemistry. 
Statistics 
Data were analyzed using ANOVA and the Bonferroni within-
groups comparison with additional testing using Dunnett’s test or 
student’s t-test. Significant differences required P values <0.05. 
Values were displayed as mean+ standard error of mean (SEM). 
Sample size (up to 14/group) was chosen in accordance to several 
previous studies of optic nerve regeneration1, 4, 18. 
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